Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs…
Elation Unveils the REBEL Profile at LDI 2024 – A Bolder Breed of Intelligent Lighting for Entertainment
Sets A New Standard In High-Performance, Versatile Lighting For Tomorrow's Creative Challenges…
Elation Unveils the REBEL Profile at LDI 2024 – A Bolder Breed of Intelligent Lighting for Entertainment
Sets A New Standard In High-Performance, Versatile Lighting For Tomorrow's Creative Challenges…
Elation Unveils the REBEL Profile at LDI 2024 – A Bolder Breed of Intelligent Lighting for Entertainment
Sets A New Standard In High-Performance, Versatile Lighting For Tomorrow's Creative Challenges…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…